Chinese answer to Alzheimer's puzzle?

Evidence of an effective new treatment for Alzheimer’s would create shock waves across healthcare given the extent of the global need among millions of patients.

But it could also be a major event in geopolitics, given what making progress in this highly complex disease would say about a country’s scientific capabilities.

So it is potentially significant that a Chinese company, Green Valley Pharmaceutical, has achieved the rare feat of getting a positive read-out in a Phase III trial in mild-to-moderate Alzheimer's disease.